INmune Bio Inc. Common stock
INMBINmune Bio Inc. (INMB) is a clinical-stage biotechnology company focused on developing novel immunotherapies to treat neurodegenerative diseases, cancer, and infectious diseases. The company's approach involves targeting specific immune pathways to modulate the immune response and improve patient outcomes. INmune Bio aims to advance therapies that leverage the body's immune system to fight various diseases more effectively.
Company News
INmune Bio announced statistically significant results from its Phase 2 MINDFuL trial of XPro1595 in early Alzheimer's disease patients. The drug showed a significant treatment effect on white matter myelin (p=0.0028) in the full study population (n=200) and strengthened further in inflammation-enriched patients (p=0.0098). The company has secure...
INmune Bio Inc. (NASDAQ: INMB) announced that Phase 2 MINDFuL trial results for XProâ„¢ (XPro1595, pegipanermin) in mild Alzheimer's disease with inflammation have been published in NPJ Dementia. In a pre-specified enriched subgroup (n=100) with amyloid-beta positivity and inflammation biomarkers, XProâ„¢ showed directionally consistent benefits ...
INmune Bio announced that the FDA has granted Fast Track designation to XPro (pegipanermin), a first-in-class selective soluble TNF inhibitor, for treating early Alzheimer's disease including mild cognitive impairment and mild dementia. The designation facilitates expedited development and review, recognizing the urgent need for treatments addres...
INmune Bio announced Q1 2026 financial results showing a net loss of $5.4 million, down from $9.7 million in Q1 2025. The company made progress on its CORDStromâ„¢ platform with a planned UK MAA submission in mid-summer, advanced XProâ„¢ to an adaptive Phase 2b/3 registrational pathway for early Alzheimer's Disease, and reported new preclinical d...
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company focused on inflammation and immunology, announced it will host a conference call on May 7th, 2026 at 4:30 PM ET to discuss Q1 2026 financial results and provide a corporate update. The company is developing treatments targeting the innate immune system across three product pla...
